HackensackUMC recognizes AcquiSci d-OSAB technology with research award

AcquiSci Inc., www.acquisci.com, today announced it has received an award from the Hackensack University Medical Center to research AcquiSci's patented d-OSAB™ technology as a device-based approach to modulating inflammation.  This preclinical study represents Phase I of a three Phase study program, and will evaluate the safety and efficacy of oxidative stress on apoptotic leukocyte induction and subsequent inflammatory cytokine modulation.  The overall program is designed to transition into a clinical stroke porcine model with primary clinical endpoints paralleling those typical in a human efficacy trial for translational relevance.  This project is being funded by the U.S. Department of Defense in support of development of candidate treatment approaches for traumatic brain injury resulting from military operations.

Dr. Chinwe Ogedegbe, Section Chief, Research Emergency Trauma Department at HackensackUMC, will be the Principal Investigator.   AcquiSci will work closely with HackensackUMC by participating in the study design and investigator meetings.

AcquiSci's CEO and inventor of the technology, Joseph Latino, stated, "This is an excellent opportunity to rigorously confirm the ability of AcquiSci's technology to reduce inflammation that is the underpinning of many diseases, in particular, traumatic brain injury.  Using the porcine stroke model, we believe that we can conclusively demonstrate a reduction in the inflammation surrounding the clot commonly attributed as a major causative phenomenon resulting in loss of cognitive and motor function loss in ischemic stroke.  Positive results in inflammation reduction in stroke modeling may be applied to traumatic brain injury and in particular, useful in military applications. HackensackUMC recognized the importance of this common inflammatory component and we are fortunate to have been able to establish this noteworthy affiliation."